Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | HPGD | P15428 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580874 | 0.82 | MEN1 (0.48) | ALDH1A1HPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL29421049 | 0.81 | PDE4C (0.49) | ALDH1A1HPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL762311 | 0.79 | NR4A2 (0.62) | NR4A2ALDH1A1HPGDSMN1; SMN2MAPK13 | |
| SCHEMBL29154651 | 0.76 | MAPK13 (0.60) | NR4A2ALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL7808125 | 0.74 | USP1 (0.61) | ALDH1A1HPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL22761529 | 0.73 | NR4A2 (0.55) | NR4A2ALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL7059841 | 0.73 | ALDH1A1 (0.73) | ALDH1A1HPGDSMN1; SMN2MEN1KMT2A | |
| Dimethylamine SCHEMBL8172161 | 0.73 | MAPK13 (0.56) | NR4A2ALDH1A1HPGDSMN1; SMN2MAPK13 | |
| SCHEMBL23949970 | 0.72 | ALDH1A1 (0.55) | ALDH1A1HPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6958523 | 0.70 | NPC1 (0.66) | NR4A2ALDH1A1HPGDSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1121129-B1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS | BRISTOL MYERS SQUIBB CO (US) | 2008-09-03 | — | — | EP | claimed |
| US-7390824-B1 | Method for treating diabetes employing an aP2 inhibitor and combination | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-24 | — | — | US | claimed |
| US-20040229807-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-11-18 | — | — | US | claimed |
| EP-1121129-A4 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL MYERS SQUIBB CO (US) | 2002-10-16 | — | — | EP | claimed |
| EP-1113801-A4 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL MYERS SQUIBB CO (US) | 2002-10-02 | — | — | EP | claimed |
| JP-2002524518-A | — | — | 2002-08-06 | — | — | JP | claimed |
| JP-2002524517-A | — | — | 2002-08-06 | — | — | JP | claimed |
| US-20020035064-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-21 | — | — | US | claimed |
| EP-1121129-A1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-08 | — | — | EP | claimed |
| EP-1113801-A1 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-07-11 | — | — | EP | claimed |
| WO-2000015230-A1 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | claimed |
| WO-2000015229-A1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | claimed |
| US-20090076033-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | ROBL JEFFREY A | 2009-03-19 | — | — | US | disclosed |
| EP-1121129-B1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS | BRISTOL MYERS SQUIBB CO (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7390824-B1 | Method for treating diabetes employing an aP2 inhibitor and combination | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-24 | — | — | US | disclosed |
| US-7358254-B2 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1121129-A1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-08 | — | — | EP | disclosed |
| EP-1113801-A1 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015230-A1 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
| WO-2000015229-A1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035064-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | SREBF2, SREBF1, AP2A2 | NR4A2 357/4885ALDH1A1 4196/4885HPGD 1519/4885 |
| US-20040229807-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | SREBF2, SREBF1, AP2A2 | NR4A2 357/4885ALDH1A1 4196/4885HPGD 1519/4885 |
| US-20090076033-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | SREBF2, SREBF1, HMGCR | NR4A2 705/4885ALDH1A1 4193/4885HPGD 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.